

Form PTO-1449 (modified)

Atty. Docket No.
4300.014500Serial No. 512008
Unknown

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Mark A. Atkinson, Sihong Song and Scott A. Loiler

Filing Date:

Concurrently Herewith

Group:

1633

Unknown

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
/SDP/	A1	6,136,597	10/24/00	Hope <i>et al.</i>	435	325	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
/SDP/	B1	WO 99/55564	11/04/99	PCT WIPO	B603	1708	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/SDP/	C1	PCT Search Report from PCT/US03/12324
	C2	Apparailly <i>et al.</i> , "Tetracycline-Inducible Interleukin-10 Gene Transfer Mediated by an Adeno-Associated Virus: Application to Experimental Arthritis," <i>Human Gene Therapy</i> , 13:1179-88, 2002
	C3	Flotte <i>et al.</i> , "Efficient Ex Vivo Transduction of Pancreatic Islet Cells With Recombinant Adeno-Associated Virus Vectors," <i>Diabetes</i> , 50:515-20, 2001
	C4	Goudy <i>et al.</i> , "Adeno-associated virus vector mediated IL-10 gene delivery prevents type 1 diabetes in NOD mice," <i>PNAS</i> , 98:13913-18, 2001
	C5	Kapturczak <i>et al.</i> , "Adeno-Associated Virus (AAV) as a Vehicle for Therapeutic Gene Delivery: Improvements in Vector Design and Viral Production Enhance Potential to Prolong Graft Survival in Pancreatic Islet Cell Transplantation for the Reversal of Type 1 Diabetes," <i>Current Molecular Medicine</i> , 1:245-58, 2001
	C6	Mah <i>et al.</i> , "Improved Method of Recombinant AAV2 Delivery for Systemic Targeted Gene Therapy," <i>Molecular Therapy</i> , 6:106-12, 2002
	C7	Song <i>et al.</i> , "Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors," <i>Proc. Natl. Acad. Sci. USA</i> , 95:14384-88, 1998
	C8	Song <i>et al.</i> , "Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors," <i>Gene Therapy</i> , 8:1299-306, 2001
↓	C9	Yang <i>et al.</i> , "Suppression of Autoimmune Diabetes by Viral IL-10 Gene Transfer." <i>J. Immunology</i> , 168:6479-85, 2002

EXAMINER: /Scott D. Priebe/

DATE CONSIDERED: 04/23/2007

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number 10512008

Filing Date 2005-08-11

First Named Inventor Mark A. Atkinson

Art Unit 1633

Examiner Name Priebe, Scott David

Attorney Docket Number 36689.42

U.S. PATENTS

Remove

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS

Remove

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS

Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10512008
Filing Date		2005-08-11
First Named Inventor	Mark A. Atkinson	
Art Unit	1633	
Examiner Name	Priebe, Scott David	
Attorney Docket Number	36689.42	

/SDP/	1	Goudy KS, , Wasserfall C, Burkhardt B, Brusko T, Song S, Ellis T, Flotte T, Atkinson MA., Elucidation of Time and Dose Dependencies Using AAV-IL-10 Gene Therapy for Prevention of Type 1 Diabetes in the NOD Mouse. Abstract No. 46. Molecular Therapy. 2002 May;5(5):Part 2 of 2 Parts. S17.	<input type="checkbox"/>
↓	2	Goudy KS, Burkhardt BR, Wasserfall C, Song S, Campbell-Thompson ML, Brusko T, Powers MA, Clare-Salzler MJ, Sobel ES, Ellis TM, Flotte TR, Atkinson MA., Systemic overexpression of IL-10 induces CD4+CD25+ cell populations in vivo and ameliorates type 1 diabetes in nonobese diabetic mice in a dose-dependent fashion. J Immunol. 2003 Sep 1;171(5):2270-8.	<input type="checkbox"/>
↓	3	Song S, Goudy K, Campbell-Thompson M, Wasserfall C, Scott-Jorgensen M, Wang J, Tang Q, Crawford JM, Ellis TM, Atkinson MA, Flotte TR., Recombinant adeno-associated virus-mediated alpha-1 antitrypsin gene therapy prevents type I diabetes in NOD mice. Gene Ther. 2004 Jan;11(2):181-6.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Scott D. Priebe/	Date Considered	04/23/2007
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.